(Meropenem + vaborbactam) is under clinical development by Melinta Therapeutics and currently in the Phase I and Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect (Meropenem + vaborbactam)’s likelihood of approval (LoA) and phase transition for Bacterial Infections took place on 20 Jan 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their (Meropenem + vaborbactam) Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

(Meropenem + vaborbactam) overview

Meropenem and vaborbactam (Vabomere, Vaborem) is a fixed dose combination drug, acts as antibacterial agent and anti infective agent. It is formulated as powder for solution for intravenous route of administration. Vabomere is indicated for the treatment of complicated urinary tract infections (cUTI), including a type of kidney infection includes pyelonephritis caused by specific bacteria in adult patients.

Meropenem (RPX2014) in combination with vaborbactam (RPX7009) is under development for the treatment of pyelonephritis and gram-negative bacterial infections including carbapenam resistant Enterobacteriaceae infections. It was also under development for the treatment of renal insufficiency and hospital-acquired pneumonia, ventilator associated pneumonia.

Melinta Therapeutics overview

Melinta Therapeutics (Melinta) is a biopharmaceutical company that focuses on the development of novel anti-infectives for the treatment of various bacterial infections. Its marketed portfolio encompasses antibiotics for the treatment of serious bacterial infections including acute bacterial skin and skin structure infections (ABSSSI), complicated urinary tract infections (cUTI), and for the prevention and treatment of other serious infections that are caused by susceptible bacteria. The company is also evaluating delafloxacin for the treatment of serious community-acquired bacterial pneumonia (CABP), meropenem and vaborbactam, oritavancin, and minocycline. Melinta’s products and pipeline candidates are built on a ribosome platform licensed from Yale University. Melinta is headquartered in New Haven, Connecticut, the US.

Quick View (Meropenem + vaborbactam) LOA Data

Report Segments
  • Innovator (NME)
Drug Name
  • (Meropenem + vaborbactam)
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Genito Urinary System And Sex Hormones
  • Infectious Disease
Key Developers
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.